Organoid Culture Seed Expansion Patents: Leaders & Trends 2026
Organoid Culture Seed Expansion Patents: Who Leads and Where Filing Is Heading
Concentrated at the top. The five most active filers together hold 41.1% of all 850 records in scope, and the ten most active hold 54.7%. Annual filings rose to a peak of 80 in 2021, then declined to 35 by 2024 — a 56% fall over that three-year span. 2025 and 2026 figures are still incomplete because publication typically lags filing by around 18 months, so the most recent years should not yet be read as a continued decline.
- 1KONINK NEDERLANDSE AKADE VAN WETENSCHAPPEN133
- 2LIFE TECHNOLOGIES CORP83
- 3CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI73
- 4EMULATE INC30
- 5STRATATECH CORP30
See the full organoid culture seed expansion analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in organoid culture seed expansion?
One assignee leads with 133 records, well ahead of the fifth-ranked filer at 30 and the tenth-ranked at 20. The top five filers combined account for 41.1% of all 850 records in scope, and the top ten account for 54.7%. This means the field has a genuine leader rather than a tightly bunched group at the top, with a long tail of single- or few-filing entrants beneath the ranked group.
Is patent filing in this field growing or slowing down?
Filings rose to a peak of 80 in 2021, then fell to 35 by 2024 — a 56% decline over that three-year span. However, publication typically lags filing by around 18 months, so 2025 and 2026 figures in the underlying data are still incomplete. It is accurate to say the field has pulled back from its 2021 peak, but not yet accurate to call the most recent one or two years a continued decline.
Which patent classes matter most for organoid seed expansion methods?
C12N, covering microorganisms and genetic engineering, appears on 95.5% of the 850 records in scope and is the structural core of this landscape. Medicinal preparations (A61K, 29.5% of records) and material testing methods (G01N, 24.0%) are the next-largest overlapping classes. Bioreactor apparatus (C12M) and enzyme/DNA measurement (C12Q) appear on a smaller share of records, around 13.9% and 9.6% respectively, indicating comparatively less-crowded claim territory around culture hardware and assay integration.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Organoid Culture Seed Expansion covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.